In the rapidly evolving landscape of wellness and metabolic research, understanding GLP1 peptide names has become essential for those tracking the latest advancements in peptide science. As an enthusiast who has spent years exploring the nuances of various research compounds, I have found that distinguishing between the diverse array of incretin mimetics is key to navigating this complex field.
Understanding the Landscape of GLP-1 Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed how we categorize metabolic research. These compounds fu Glucagon-likepeptide-1 (GLP-1) analogues ; Exenatide, AGLP-1agonist used in the management of type 2 diabetes mellitus. ; Liraglutide, AGLP-1analog used in Read more nction by mimicking the physiological role of the GLP-1 hormone, which is naturally produced in the intestine.
When reviewing the current market, it is helpful to categorize them by their chemical nomenclature and their associated brand names. For instance, Ozempic (semaglutide) and Victoza (liraglutide) are perhaps the most recognizable entries in this category. However, the list of available agents is extensive and includes:
* Semaglutide: Found under trade names such as Ozempic, Wegovy, and Rybelsus. It is widely considered one of the most studied compounds in the class.
* Tirzepatide: Marketed as Tirzepatide (Zepbound®, Mounjaro®), this molecule is unique as it functions as a dual GLP-1/GIP receptor agonist.
* Liraglutide: Often identified as Liraglutide, Victoza®, Novo Nordisk, or in its weight-management formulation, Saxenda®.
* Dulaglutide: Commonly referred to as Dulaglutide (Trulicity®).
* Exenatide: Available in various forms, including exenatide, exenatide once weekly, and liraglutide, as well as Bydureon® and Byetta®.
* Lixisenatide: Another notable agonist, often associated with Adlyxin® or Lyxumia®.
* Albiglutide: Included in the broader list of Exenatide, Liraglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide.
Emerging Research and Future Directions
The field is not limited to these established names. Researchers are constantly investigating new molecules, such as Retatrutide Mar 23, 2026—Retatrutideis a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity.Read more , which is being studied as a triple hormone (GIP, GLP-1, and glucagon) receptor agonist. The scientific literature frequently highlights that tirzepatide and semaglutide are currently the two most prominent categories in modern research.
When discussing GLP-1 compounds, it is also common to see them grouped with other specialized peptides that support different physiological goals. For example, many individuals interested in cellular repair or optimization often look into BPC-157 (for tissue healing and gut repair) or CJC-1295/Ipamorelin to complement their research stack.
Navigating the Terminology
For those just beginning to look into these compounds, the names can be confusing. It is important to remember that Ozempic and Rybelsus are brand names for the drug semaglutide, just as Glucagon-like peptide-1 (GLP-1) is the foundation for all these diverse agents. Whether considering GLP-1 Drugs Approved in the Uni Dec 1, 2025—Dulaglutide (Trulicity). Exenatide/ER. Liraglutide (Victoza). Semaglutide (Ozempic, Rybelsus). Tirzepatide (Mounjaro).GLP-1Agonists may be Read more ted States or evaluating global research trends, the distinction between the base peptide and the commercial delivery system is vital.
Final Thoughts on Research Optimization
My personal approach to this subject has always been rooted in data and observation. While many seek out the top 5 peptides that can safely enhance your GLP-1 weight loss journey, it is crucial to maintain a focus on the underl Glucagon-like peptide-1 analogues: An overview - PMC ying science. Whether you are analyzing Semaglutide, Tirzepatide and Retatrutide or investigating the difference between exenatide, liraglutide, Exenatide extended-release, the focus should always be on understanding how these molecules interact with metabolic pathways.
As someone who views peptide research as a long-term educational end Dec 1, 2025—Dulaglutide (Trulicity). Exenatide/ER. Liraglutide (Victoza). Semaglutide (Ozempic, Rybelsus). Tirzepatide (Mounjaro).GLP-1Agonists may be Read more eavor, I find that keeping a clear list of these What is the Difference Between GLP-1, GLP-2, and GLP-3? compounds—from the established to the experimental—is the best way to s Apr 23, 2023—9 GLP-1 receptor agonist hypoglycemic drugs have been approved for marketing in the world, namely:exenatide, liraglutide, Exenatide extended-release( Read more tay informed in this fascinating area of study.